Drugs / AbGn-7
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01466569 | Nov 2011 → Jan 2013 | epithelial neoplasm, gastric cancer | AbGenomics B.V Taiwan Branch | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AbGn-7 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01466569 ↗ |
| Action | Deplete | “AbGn-7 was identified based on its direct killing (apoptosis-inducing) activities towards cancer cells expressing its epitope.” NCT01466569 ↗ |
| Route | Intravenous | “weekly iv infusion” NCT01466569 ↗ |